title: Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
abstract: Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatment are urgently needed. Herein, we review the mechanisms and utility of poly (ADP-ribose) polymerase inhibitors in combination with radiation therapy as a treatment option for GBM patients and the role of phosphatase and tensin homologue mutations as a biomarker of response.
authors.affiliation: University of NSW, Kensington, NSW, Australia.
authors.forename: A
authors.initials: A
authors.lastname: Lester
authors.affiliation: University of NSW, Kensington, NSW, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Rapkins
authors.affiliation: University of NSW, Kensington, NSW, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Nixdorf
authors.affiliation: University of Sydney, NHMRC Clinical Trials Centre, Camperdown, NSW, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Khasraw
authors.affiliation: University of NSW, Kensington, NSW, Australia. k.mcdonald@unsw.edu.au.
authors.forename: K
authors.initials: K
authors.lastname: McDonald
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics; D001932:Brain Neoplasms / Q000235:genetics* / Q000628:therapy; D059248:Chemoradiotherapy; D005909:Glioblastoma / Q000235:genetics* / Q000628:therapy; D006801:Humans; D009154:Mutation / Q000235:genetics*; D051059:PTEN Phosphohydrolase / Q000235:genetics*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use*; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
keywords: Biomarkers; Glioblastoma; PARP inhibitor; PTEN